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Abstract
In many phase II trials in solid tumours, patients are assessed using endpoints based on the Response
Evaluation Criteria in Solid Tumours (RECIST) scale. Often, analyses are based on the response rate.
This is the proportion of patients who have an observed tumour shrinkage above a pre-defined level and
no new tumour lesions. The augmented binary method has been proposed to improve the precision of the
estimator of the response rate. The method involves modelling the tumour shrinkage to avoid dichotomising
it. However, in many trials the best observed response is used as the primary outcome. In such trials,
patients are followed until progression, and their best observed RECIST outcome is used as the primary
endpoint. In this paper, we propose a method that extends the augmented binary method so that it can
be used when the outcome is best observed response. We show through simulated data and data from a
real phase II cancer trial that this method improves power in both single-arm and randomised trials. The
average gain in power compared to the traditional analysis is equivalent to approximately a 35% increase
in sample size. A modified version of the method is proposed to reduce the computational effort required.
We show this modified method maintains much of the efficiency advantages.
1 Introduction
A new cancer treatment is tested for potential benefit in phase II trials that use a relatively small number
of patients followed over a short period of time. The results of the phase II trial determines whether to
test the treatment in a larger, more time-consuming, and more costly phase III trial. Because of the high
cost of, and high failure rate in, phase III oncology trials [8], it is important to improve the analysis of
Phase II trials to ensure the decision is more accurate.
Phase II oncology trials use a variety of endpoints to evaluate the efficacy of a treatment [6, 9]. The
most commonly used endpoints are based on the Response Evaluation Criteria in Solid Tumours (RECIST)
scale [2]. RECIST defines tumour size as the sum of longest diameters of target lesions and categorises
patients into complete response (CR), partial response (PR), stable disease (SD), and progressive disease
(PD). CR and PR represent no new tumour lesions and a 100% shrinkage and greater than 30% shrinkage,
respectively; PD represents a 20% increase in tumour size from the minimum size observed up to that point,
or new lesions appearing. Often patients are followed until they are categorised as PD or a preplanned time,
and patients with CR or PR are labelled responders. The response rate is defined as either: 1) proportion
of patients who are responders at a certain time after baseline (fixed response); or 2) the proportion of
patients whose best observed response before progression is CR or PR (best observed response, BOR).
Categorizing patients into responders and non-responders is widespread and clinically appealing. How-
ever, it can have substantial statistical disadvantages. Its major limitation is that it dichotomises the
continuous tumour variable, thus discarding information. This loses substantial efficiency [1]. Some re-
searchers have addressed the problem and proposed methods to make use of the continuous change in
tumour response to improve statistical efficiency. This is done in different ways. Karrison et al. [7] propose
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directly using the change in tumour size as an endpoint. Wason and Seaman [12] use models for the tumour
size and new lesion data which can be used to infer the fixed response rate with higher precision. Jaki et
al. [5] propose a method that links tumour size change with mortality using historical datasets. Authors
have demonstrated that using continuous scales can increase the power (or reduce the required sample for
a target power) compared to analysing the binary composite outcome.
The method of Wason and Seaman [12] retains the clinically meaningful endpoint but takes into account
the continuous information on tumour size. This method is limited by only allowing two follow-up visits,
and only considering response rate at not only a fixed time (i.e. it cannot be used to make inferences on
BOR). In trials that patients are assessed two times (interim and final), their method is sufficient. However,
in trials that patients are followed up until a pre-planned time, a method incorporates information on all
measurement data is preferred. In this paper we present an extended method that can be used for any
number of follow-up times for fixed response or BOR. We propose a modified version that uses a highly
efficient technique for multivariate integration [3], which substantially reduces the computation time taken.
We assess the properties of the proposed methods by using simulated data and data from a real phase II
cancer trial (HORIZON II).
This paper is divided into four sections. Section 2 gives a brief overview of the augmented binary
method [12]. It then describes the proposed extensions of the method. Section 3 evaluates the performance
of the proposed methods using simulations and real data. Section 4 summarizes the results and presents
limitations and future work.
2 Methods
2.1 Background
We use the phrase ’tumour size’ as shorthand for the sum of the longest diameter of target tumour lesions.
We assume patients’ tumour sizes are recorded until progression occurs or until a preplanned number
of visits. We note there are two ways in which a progression can occur: an increase in tumour size by
more than 20 % (a tumour-growth progression) or new lesions appearing (a new-lesion progression). Two
response endpoints can be used in the analysis, one being fixed time and the other being BOR. Analysis at
a fixed time t uses the proportion of responders at time t (those who have a tumour size shrinkage at time
t above a pre-defined threshold and no progression up to that point). BOR defines patients as a responder
or not according to their best observed response before progression. The latest RECIST guidelines [2] give
BOR two definitions according to whether confirmation is required or not. Confirmation means that an
apparent response must be backed up by continued response at the next timepoint to be counted as genuine.
This is especially recommended for single-arm trials. When confirmation is not required (randomised trials
comparing two arms), BOR is defined as the best response across all time points up to progression. When
confirmation is required, BOR is defined as a response if the patient is a responder at two consecutive time
points before progression.
2.2 Notation
Tumour sizes for each patient are measured at several discrete times (T denoting the maximum time).
The tumour size at time t for patient i is denoted by zit where t = 0 represents the baseline measurement.
We denote G and X as the time at which a tumour-growth progression and new-lesion progression occurs,
respectively. Once a patient progresses they are no longer followed up. The observed data is therefore
(Fi, zi) where Fi=min(Xi, Gi, T ). We define yit as the log tumour size ratio for patient i at time t,
yit = log(zit/zi0), and ct as the pre-specified dichotomisation threshold for response (on the log tumour
ratio scale). Further, Dit defines new-lesion progression indicators: {Dit = 1 if patient i has a progression
due to new lesions occurring between time (t − 1) and t, t = 1, . . . , T }. We define composite response
indicators corresponding to the definitions of fixed time and BOR as follows.
For fixed time at time t, the composite response indicator Sit for patient i is defined as
Sit =
{
1, if Dij = 0 for all j = 1, . . . , t and yit < ct
0, otherwise
.
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For BOR when confirmation is not required, the event is equivalent to having at least one record
classified CR/PR before progression or time T , the response indicator BORi is defined as
BORi =
{
1, if there exists a t such that yit < log(0.7), t ≤ min(Fi, Xi − 1)
0, otherwise
.
We consider the case where confirmation is required later.
2.3 Estimating response probability using the augmented binary method with
two follow-up times
The augmented binary method, henceforth referred to as AugBin, was proposed by Wason and Seaman [12].
We briefly describe this method here, but more details are found in [12].
The AugBin method makes assumptions that the log tumour size ratios follow a multivariate normal
distribution, and the probability of new-lesion progression depends only on the observed tumour size at
the previous visit. The log tumour size ratios are modelled by
(Yi1,Yi2)
′|zi0 ∼ N((µi1, µi2)′,Σ),
and the new-lesion progression is modelled by using logistic regression models
Logit{Pr(Di1 = 1|zi0)} = α1 + γ1zi0,
Logit{Pr(Di2 = 1|Di1 = 0, zi0, zi1)} = α2 + γ2zi1.
The probability of response for patient i is written by:
Pr(Si = 1|θ) =
∫ c2
−∞
∫ ∞
−∞
Pr(Di1 = 0|zi0)Pr(Di2 = 0|D1 = 0, zi0, zi1)fY1Y2(yi1yi2; θ)dyi1dyi2,
where θ is the vector of parameters from the above models and c2 is the dichotomisation threshold (usually
log(0.7), representing at least a 30% shrinkage in the tumour size from baseline). The mean response
probability is estimated by Pr(S = 1|θˆ) = 1n
∑n
i=1 Pr(Si = 1|θˆ), where θˆ is the maximum likelihood
estimator of θ. A program is available in the paper which uses R2Cuba to compute the above integration.
An approximately (1-α) % confidence interval for the probability of response is constructed on the logit
scale, that is, expit
{
l(θˆ)±Φ−1(1− α2 )
√
var(l(θˆ))
}
, where l(θ) = Pr(Si=1|θ)1−Pr(Si=1|θ) and var(l(θˆ)) is obtained by
using the delta method.
2.4 Extended augmented binary method at a fixed time (t>2)
We use the same assumptions and extend the AugBin method to t follow-up times. The log tumour size
ratios are modelled by
(Yi1, . . . ,Yit)
′|z0 ∼ N((µi1, . . . , µit)′,Σ). (1)
An unstructured covariance matrix is used (although an alternative form may be needed if t is large
enough). The new-lesion progression is modelled by
Logit{Pr(Dit = 1|Di1 = . . . = Di(t−1) = 0, zi0, . . . , zi(t−1))} = αt + γtzi(t−1). (2)
We assume that the new-lesion progression depends only on the previous observed rumour size. The
missing tumour size because of new-lesion progression can be, therefore, treated as MAR as justified
in [12]. We assume data (Yi1, . . . , YiFi) before progression is always observed and (YiFi+1 , . . . , YiT ) is
always missing, similarly for (Di1, . . . , DiFi) and (DiFi+1 , . . . , DiT ). The data (Y1, . . . , YT , D1, . . . , DT ) is
the case of monotone missingness. The probability of response for patient i at time T can be written by:
Pr(SiT = 1|θ) =
∫ cT
−∞ . . .
∫∞
−∞
T∏
t=1
Pr(Dit = 0|Di1 = . . . = Di(t−1) = 0, zi0, . . . , zi(t−1))
×fY1,...,YT (yi1, ..., yiT ; θ)dyi1...dyiT
(3)
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The advantage is that the Equation (3) uses the models to estimate probability of response of patients
and missing data are MAR, it can be applied to patients who drop out before preplanned time. The
probability is interpreted as the probability of patient i being a responder at time T as if they were
observed until T. A potential issue of Equation (3) is that the multivariate integration is computationally
intensive. The mean response probability is estimated by averaging response probability over n patients
given θˆ. An approximately (1-α) % confidence interval is constructed as described in 2.3.
2.5 Modified augmented binary method at a fixed time
The objective for this section is to efficiently estimate the mean response probability using continuous
tumour-size information in a computationally efficient way. We assume that {no new-lesion progression
occurs from time 1 to time T} and {no tumour-growth progression} are conditionally independent given
tumour size z¯t−1 = (z0, . . . , zt−1). We note this is a strong assumption, and assess the sensitivity to this
assumption later on. The probability of response for patient i at a fixed time t can be written by
Pr(response|z¯t−1) = Pr(no new-lesion progression until t|z¯t−1)
×Pr(no tumour progression at time t|z¯t−1 ).
Let pit be the probability of new-lesion progression at time t, t = 1, . . . , T . Note that pit is a conditional
probability given no new-lesion progression occurring at previous timepoints. The log tumour size ratio
Yi is allowed to depend on baseline tumour size whereas new-lesion progression depends on the previous
observed tumour size at the previous visit. We can model Y by
(Yi1, . . . ,Yit)
′|z0 ∼ fYi(·), l(piit) = β0 + βtzi(t−1). (4)
where fY (·) is a joint distribution, and l(·) is the logit link function. We assume that piit(z¯t−1) = piit(zt−1).
The probability of response for patient i at a fixed time T can be written by
Pr(Si = 1|z¯t−1, θ) =
T∏
t=1
{1− piit(z¯t−1, θ)}
∫ cT
−∞
∫ ∞
−∞
...
∫ ∞
−∞
fY1,...,YT (yi1, ..., yiT |zi0, θ)dyi1...dyiT , (5)
where cT is the dichotomisation threshold and θ is a vector of parameters of the models. We assume that
fY (·) is the pdf of a multivariate normal distribution. The multivariate integration can then be calculated
by a highly efficient technique proposed by Genz and Bretz [3]. The value of piit is estimated by using
l(pˆiit) if zi(t−1) is observed. For patients who have progressed, their records at time (Fi + 1), . . . , T are not
observed. Their probability of new-lesion progression at time t, t > Fi is estimated by
p˜iit =
1
nt − k
∑
j,yjt∈ϕ
pijt (6)
where nt is the number of patients with observed zt−1 and k is the number of patients who have log
tumour size ratio yt outside of the region of integration ϕ of Equation (5). We trim those k patients to
avoid underestimating pit. This is similar to an idea of trimmed mean, which is used in many areas and
has advantages under both normal and non-normal distributions [11,13].
The vector θ consists of {(T+1)+ T(T+1)/2 + 2T } parameters (the µ and Σ parameters from the
multivariate normal and parameters from the logistic regression models). The mean response probability
is estimated by Pr(S = 1|θˆ) = 1n
∑n
i=1 Pr(Si = 1|θˆ), where θˆ is the maximum likelihood estimator of θ. A
(1− α) % confidence interval for Pr(S = 1|θ) can be constructed :[
Pr(S = 1|θˆ)− Φ−1(1− α/2)
√
Var(Pr(S = 1|θˆ)), Pr(S = 1|θˆ) + Φ−1(1− α/2)
√
Var(Pr(S = 1|θˆ))
]
,
where Φ is the standard normal distribution function. However, we found that the method has better prop-
erties if we find a confidence interval for logit{Pr(S = 1|θˆ)} and transform back. Let l(θ) = log Pr(Si=1|θ)1−Pr(Si=1|θ) ,
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we obtain Var(l(θˆ)) by using the delta method, which is written by
var(l(θˆ)) ≈ (∇l(θˆ))Tvar(θˆ)∇l(θˆ),
where ∇l(θˆ) is the partial derivatives of l(θ). An approximately (1-α) % confidence interval for the
probability of response is[
expit
{
l(θˆ)− Φ−1(1− α/2)
√
var(l(θˆ))
}
, expit
{
l(θˆ) + Φ−1(1− α/2)
√
var(l(θˆ))
}]
.
To summarise, the modified method uses a simplification for the relationship between new-lesion pro-
gressions and tumour-growth progressions in order to use a more efficient procedure for multivariate
integration.
2.6 Proposed method for best observed response (BOR)
We focus on the case where confirmation is not required but show briefly how the methodology can
straightforwardly allow for confirmation later. By the definition of BOR, a patient is a responder if they
have at least one log tumour size ratio smaller than log(0.7) before progression or maximum follow-up
time. We define Ω1 = (log(0.7), log(1.2)), Ω2 = (−∞, log(0.7)), and Ω3 = (−∞,∞) as the possible regions
of integration corresponding to being classified as stable disease, responder, and irrelevant variables. Let
h be the time at which the patient is first classified as CR/PR. Hence, each component of Y¯T will fall into
one of the three regions as
(Y1 . . . Yh−1 ∈ Ω1, Yh ∈ Ω2, Yh+1 . . . YT ∈ Ω3). (7)
The probability of response using BOR for patient i will be the sum over all possibilities of when the
CR/PR is first observed. Following the concept of the extended augmented binary approach (eAugbin),
the probability of response can be written by :
Pr(BORi = 1|θ) =
T∑
h=1
∫
ΩT−h3
∫
Ω12
∫
Ωh−11
h∏
t=1
Pr(Dit = 0|Di1 = . . . = Di(t−1) = 0, zi0, . . . , zi(t−1))
×fY1,...,YT (yi1, ..., yiT ; θ)dyi1...dyiT .
(8)
Similarly, following the concept of the modified augmented binary approach (mAug), the probability
of response can be written by:
Pr(BORi = 1|z¯t−1, θ) =
T∑
h=1
h∏
t=1
{1− piit(z¯t−1, θ)}
∫
ΩT−h3
∫
Ω12
∫
Ωh−11
fY1,...,YT (yi1, ..., yiT ; zi0, θ)dyi1...dyiT . (9)
The mean response probability is then estimated by 1n
∑n
i=1 Pr(BORi = 1|θˆ), where θˆ is the maximum
likelihood estimator of θ. As before, we work on the logit scale, use the delta method to obtain the variance,
and then transform back to construct the confidence interval for the mean response probability.
When confirmation is required, having two continued responses of CR/PR before progression, one can
replace (7) with (Y1 . . . Yh−1 ∈ Ω1, Yh, Yh+1 ∈ Ω2, Yh+2 . . . YT ∈ Ω3) with the sum in (9) going from 1 to
T − 1.
2.7 Testing a difference in probability of response between two treatments
The above methods can be applied to single-arm trials. For a randomised trial where comparing the
difference in response probability is of interest, a minor addition is required.
We assume 2n patients are recruited with n patients randomised to each arm. Assumptions for log
tumour size ratios and new-lesion progression remain the same as in Section 2.4. We introduce an arm
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indicator R to the models, with 0 for control and 1 for experimental arms. The log tumour size ratios are
modelled by
(Yi1,Yi2, . . . ,YiT )
′|R, z0 ∼ N((µi1, µi2, . . . , µiT )′,Σ),
the new-lesion progression for T > t is modelled by using logistic models
Logit{Pr(Dit = 1|Di1 = . . . = Dit−1 = 0, zi0, . . . , zi(t−1))} = αt + βtR + γtzi(t−1).
The probabilities of new-lesion progression for control and experimental arms are [1+exp{−(αt+γtzi(t−1))}]−1
and [1 + exp{−(αt+βt+γtzi(t−1))}]−1, respectively. Let θ be the vector of (T 2 + 9T2 + 2) parameters from
the above models. The mean response probability at a fixed time is estimated by
Pr(S = 1|θˆ,R) = 1
2n
2n∑
i=1
Pr(Si = 1|θˆ,R),
where θˆ is the maximum likelihood estimator of θ. We note that patients from both arms are included
in the calculation of the probability of response in an arm, as is recommended and justified in [12]. The
mean difference in response probability at a fixed time is defined as the difference between mean response
probabilities for the two arms. It can be written by
mF (θ) = Pr(S = 1|R = 1, θ)− Pr(S = 1|R = 0, θ).
We obtain the variance of mF (θˆ) by using the delta method and use the Wald test to test whether mF (θ)
is zero. Similarly, we define the mean difference in response probability for BOR as
mB(θ) = Pr(BORi = 1|R = 1, θ)− Pr(BORi = 1|R = 0, θ).
Both the extended and modified methods can be used as in previous sections.
3 Results
In this section, we evaluate the performance of the proposed methods in terms of precision and power
using simulations and a real data example. We use “Bin” to represent the method that just analyses
the response outcomes as binary. For single-arm trials, the binary method uses the R-package Hmisc to
construct a Wilson interval for binary success (S = 1 or BOR = 1). For two-arm studies, the binary
method is a logistic regression model that has parameters for treatment group and baseline tumour size,
from which the treatment effect can be tested. The terms “Augbin”, “eAugbin”, and “mAug” refer to
methods that use continuous information. They are, respectively, Wason and Seaman’s method [12] at
two-follow up times, the extended method for more than two-follow up times, and the modified method for
rapid computation. We use fixed time with varying numbers of follow-up times and best observed response
without confirmation as the endpoints.
3.1 Simulation study setup
Following the aforementioned notation, the observed data available for each patient is (Fi, zi). The observed
data are simulated as follows. First of all, baseline tumour size zi0 for patient i is generated from a
uniform distribution and log tumour size ratios of T follow-up time {yit : t = 1, . . . , T} are generated
from a multivariate normal distribution. Tumour size zit can then be calculated from zit = e
yitzi0. Next,
new-lesion progression indicators are generated from logistic models with intercept α and tumour size
effect γ. A non-zero γ means that probability of new-lesion progression depends on the tumour size at
the previous timepoint. We define time to new-lesion progression as the first time when the new-lesion
progression occurs from the logistic models. Finally, tumour size observations of patient i after progression
are replaced as missing.
6/12
3.1.1 Single-arm trials assessing response at fixed time
Before generating 5000 replicates, we test the computation time for running one replicate using Aug-
bin/eAugbin. We generated one replicate of 75 patients. Baseline tumour size (Z0) is generated from a
uniform distribution and log tumour size ratios are generated from a multivariate normal distribution for
2 to 6 follow-up times. The (α, γ) are set to (-1.5,0) and (-2.5,0.2). The value of α = −1.5 corresponds
to an 18 % chance of developing new lesions between each visit. The computation time for running one
replicate using Augbin/eAugbin for 2 to 6 follow-up times are 0.04, 0.65, 2.28, 3.41 and 4.47 minutes;
while mAug at 6 follow-up times takes 0.09 minutes. We do not consider T > 4 because of the length of
time need to simulate 5000 replicates for eAugbin. The simulation settings of log tumour size ratios for 2
follow-up times is a similar formulation to [12], that is
Z0 ∼ U(0, 1),Y2 ∼ N
[
log(0.7)
(
.5
1
)
,
(
.5 .5
.5 1
)]
.
The settings for T=3 and 4 are: Z0 ∼ U(0, 1),
Y3 ∼ N
log(0.7)
 .5.75
1
,
.5 .5 .5.5 .75 .75
.5 .75 1
 ,Y4 ∼ N
log(0.7)

.25
.5
.75
1
,

.25 .25 .25 .25
.25 .5 .5 .5
.25 .5 .75 .75
.25 .5 .75 1

 .
Table 1 shows mean estimated response probability and coverage for Bin, Augbin/eAugbin and mAug
for 2,3,4 follow-up times for 5000 replicates. The columns 10-11 show the reduction in 95% confidence
interval (CI). They are, respectively, the average of [1-(CI width of Augbin)/(CI width of Bin)] and [1-(CI
width of mAug)/(CI width of Bin)]. As seen, in all cases, eAugbin and mAug have narrower CIs compared
with Bin. For example, mAug reduces CI width by 14% means that Bin needs an additional 30% sample
size to obtain a similar width. The mAug has a similar coverage to Augbin at t = 2. For larger t, it appears
the mAug method has a better coverage probability (i.e. closer to the nominal value) than eAugbin. The
reduction in confidence interval width, compared to the binary method, appears to be similar for the two
methods. Thus for single-arm trials it appears mAug shows a significant improvement in computational
efficiency without notably poorer statistical characteristics compared to eAugbin.
3.1.2 Randomised trials using response at fixed time
We consider a two-arm trial with a control and experimental arm for 2 follow-up times. Each arm has 75
patients that have been allocated at random. Baseline (Z0) is generated from a U(0, 1) distribution. The
mean log tumour size ratios between each visit are generated from a normal distribution with mean µ and
variance 12 . We set µ = log(0.7) + δτ +ψ, where δ = 1 for control and δ = −1 for experimental arms, 2τ is
the difference in the mean log tumour size ratio and ψ reflects the effectiveness of the control treatment.
This is a similar formulation as [12].
Figure 1 compares the powers for Bin, eAugbin and mAug methods for randomised trials. The figure
on the right shows the power over treatment effect when τ =.35. As seen, there is a clear power gain when
using either mAug or Augbin. mAug performs very closely to Augbin. The empirical Type I error when
the difference is 0 for Augbin and mAug are 0.054 and 0.055, respectively.
3.1.3 Non-comparative trials for BOR
Using the binary composite outcome, patients are classified as responders if they have a CR/PR before
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time F. The computation time for running one replicate using Augbin/eAugbin and BOR for 3 to 6 follow-
up times are 0.05, 0.09, 0.3 and 0.56 minutes; while mAug at 6 follow-up times takes 0.22 minutes. Again
we use 5000 replicates of 75 patients. Baseline tumour size is generated from a uniform distribution (0,
1). The log tumoursize ratios are generated from multivariate normal distribution for 4,5,6,7 follow-up
times with σ2tt = 1, t = 4, 5, 6, 7. Regardless of the number of visits after baseline, we set the mean log
tumour size ratios at the end of the treatment to log(0.7). For example, the case where T=4 refers to
having 4 visits after baseline and µ being set to log(0.7) [.25 .50 .751]. For computational reasons, eAugbin
was included for up to T=6. Tables 2 show the operating characteristics of mAug and Bin for maximum
number of visits varying from 4 to 7. Overall, mAug reduces the average width of the CI by at least 16
% compared with Bin. This is equivalent to needing a sample size of around 101 (1.162 × 75), to obtain
a similar average width using Bin. The reduction in width is slightly higher when there is a tumour size
effect on new-lesion progression.
3.1.4 Comparative trials for BOR
To illustrate results of the mAug method for a two-arm trial, we consider the case where each arm has 75
patients and patients are followed for 4 time points. The mean log tumour size ratios for each time point
is (log(0.7) + .25δτ), (log(0.7) + .5δτ), (log(0.7) + .75δτ), and (log(0.7) + δτ), where δ = 1 for control and
δ = −1 for experimental arms respectively. Figure 2 compares the powers for Bin and mAug methods in
comparative trials for four time points when best observed response is used. Although there is a slight
inflation in Type I error rate for mAug, in general, there is a consistent power advantage when using mAug
compared to using Bin. The empirical Type I error when the difference is 0 for Binary and mAug are
0.041 and 0.058, respectively.
3.2 Case study: HORIZON II
HORIZON II (clinicaltrials.gov identifier: NCT00384176) is a three arm colon cancer trial sponsored by
AstraZeneca. Patients initially were randomly assigned 1:1:1 to placebo, cediranib 20 mg once daily,
cediranib 30 mg once daily. Later, subsequent patients were randomly assigned 1:2 to placebo or cediranib
20 mg [4]. The numbers of patients with baseline record for the three arms are 346, 484, 209, respectively.
The tumour sizes of patients were measured every 6 weeks up to 24 weeks and then every 12 weeks. Figure
S1 in supporting information shows a waterfall plot for the individual reduction in tumour size at week 24
from the baseline. There are cases that participants are classified as responders before progression which
results in different response estimates between fixed time and BOR.
We used a permutation test to calculate the empirical type I error rate. Data from baseline, 6, 12,
18, and 24 weeks were used. We simulated 5000 replicates, with the treatment assignment label shuffled
randomly in each replicate, For each replicate, we tested the difference in probability of best observed
response between two treatment arms using mAug with 4-follow up times. The empirical Type I error for
no difference between placebo and cediranib 20 mg is 0.0558 and that between placebo and cediranib 30
mg is 0.0518. These are within Monte Carlo standard error of a true type I error of 0.05 (MC error +/-
0.006).
Figure S2 in supporting information shows the mean estimated response probability using the three
methods and fixed time with between 2 and 5-follow up times for Placebo, 20 mg and 30 mg, respectively.
The mean estimated response probability decreases as the number of timepoints increases. Generally, the
estimated mean probabilities of response for three methods are similar.
Table 3 reports the width of the 95% CI for each arm’s probability of response using fixed time. The
width corresponds to the length of the vertical lines shown in Figure S2. The 95% CI widths of eAugbin
and mAug are considerably narrower than that of Bin. We compared Placebo and cediranib 20 mg as well
as Placebo and cediranib 30 mg using mAug BOR and Bin BOR for 4-6 time points. Results show that
the mAug method gives a considerably smaller 95% CI than the Bin method. The maximum width of the
95% CI for mAug is 0.131 for comparing Placebo with 30 mg, while the width is 0.174 for Bin (See Table
S2 in supporting information).
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4 Discussion
In this paper we have considered how the augmented binary method of [12] can be extended to be applicable
for a wider range of phase II oncology trials. We have made three contributions. The first is to extend the
existing method to more than two follow-up times. The second is a modified method that considerably
reduces the computational time by making a simplifying assumption about the relationship between new
lesions and tumour size change. The third is a mechanism for using both of these methods when the
endpoint is based around the best observed RECIST observation before progression, which is a common
phase II oncology endpoint.
We have shown that all proposed methods carry the same good properties as the augmented binary
method. They provide extra precision, i.e. they require a smaller sample size for the same precision
(compared to the traditional analysis of analysing response as a binary outcome) in single arm trials and
are more powerful in comparative trials.
The difference between the modified(mAug) and extended method (eAugbin) is that the former uses
the estimated probability of new-lesion progression whereas the latter more correctly incorporates variation
by averaging all possibilities. Estimation of probabilities using the modified method might be biased if
only a few patients remain in a trial at some timepoint. The mAug has similar properties to eAugbin with
respect to precision and power when using BOR.
The extended and modified methods define progression as 20% increase from baseline, whereas RECIST
defines progression as 20% increase from the minimum point observed. On the HORIZON II dataset,
we examined the number of patients who had their best observed response being PR or CR by both
of these definitions. The number is the same for both approaches for all number of follow-up times.
This indicates that considering progression as being 20% from baseline does not substantially affect the
estimation. However, we should point out that the eAugbin would be able to use the RECIST definition
of progression by including a suitable indicator variable in the integrand as well as mAug by changing
regions of integration of variables.
All proposed augmented binary methods involve modelling the log tumour size ratio and new-lesion
progression indicators. An alternative approach is joint latent modelling of longitudinal tumour size data
and the new-lesion progression. One can use a random effect model for the repeat tumour size measure,
and a latent class membership for new-lesion progression. By membership, we mean a participant has
probabilities of belonging to latent classes. Each class refers to the time when new-lesion progression
occurs. Moreover, tumour-growth progression or new lesions appearing at a time period results in the
patient’s tumour size measure being missing for all subsequent time periods. Considering this monotone
missing pattern in log tumour size, the joint probability of log tumour size can be written as the product
of a set of conditional probabilities of current log tumour size ratio given previous data [10]. Future work
is warranted to investigate whether this more complicated methodology is worth applying.
We have only considered response end-points in this work. An increasingly commonly used phase II
endpoint is progression-free-survival (PFS). Further development of the augmented binary method so that
it can be applied to improve analyses of PFS is an area of current work.
5 Software
A package mAugbin in R is available at https://sites.google.com/site/jmswason/supplementary-material
for the methods proposed in this work. The package includes extend augment binary method, which is more
computationally intensive, as well as modified augmented binary method, which required an assumption
for estimating the probability of response for fixed time and for best observed response.
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Table 1. Mean estimated probability of response and coverage of the modified augmented binary method
(mAug) in comparison with using dichotomised continuous method (Bin), augmented binary method
(Augbin) and extended augmented binary method (eAugbin) using fixed time with varying numbers of
follow up times.
Scenario Mean of estimated probability Estimated coverage Reduction in width of 95% CI(%)
(α, γ) Time True Bin Augbin/ mAug Bin Augbin/ mAug Augbin/ mAug
eAugbin eAugbin eAugbin
(-1.5, 0) 2 0.334 0.333 0.332 0.338 0.957 0.947 0.947 15.68 14.75
(-2.5, 0.2) 2 0.293 0.293 0.293 0.286 0.948 0.945 0.941 13.45 11.94
(-1.5, 0) 3 0.318 0.316 0.314 0.317 0.953 0.936 0.949 12.53 13.26
(-2.5, 0.2) 3 0.450 0.444 0.443 0.443 0.954 0.943 0.948 14.5 15.28
(-1.5, 0) 4 0.270 0.268 0.263 0.268 0.949 0.926 0.95 12.67 12.54
(-2.5, 0.2) 4 0.429 0.422 0.421 0.421 0.957 0.938 0.943 13.14 14.41
Table 2. Mean estimated probability of response and coverage using best observed response (BOR)
without confirmation with Bin, eAugbin and mAug for maximum number of visits from 4 to 7.
Mean of estimated probability Estimated coverage Reduction in width of 95% CI(%)
(α, γ) n Time True Bin eAugbin mAug Bin eAugbin mAug eAugbin mAug
(-1.5, 0) 75 4 0.4 0.4 0.404 0.403 0.959 0.954 0.955 16.5 15.9
(-1.5, 0) 75 5 0.391 0.393 0.398 0.396 0.943 0.951 0.952 16.6 15.9
(-1.5, 0) 75 6 0.386 0.39 0.395 0.394 0.959 0.954 0.955 16.7 16
(-1.5, 0) 150 7 0.382 0.382 — 0.387 0.944 — 0.957 — 16.6
(-2.5, 0.2) 75 4 0.46 0.457 0.462 0.461 0.941 0.957 0.957 16.8 17.3
(-2.5, 0.2) 75 5 0.452 0.448 0.454 0.452 0.954 0.96 0.96 18.2 17.2
(-2.5, 0.2) 75 6 0.446 0.442 0.449 0.447 0.942 0.962 0.961 18.3 17.2
(-2.5, 0.2) 150 7 0.441 0.441 — 0.446 0.95 — 0.96 — 18.3
Table 3. The width of 95% CI for 3 methods using fixed time with between 2 and 5-follow up times for
individual arm.
Placebo Cediranib 20 mg Cediranib 30 mg
Method \ Time 2 3 4 5 2 3 4 5 2 3 4 5
Bin 0.113 0.114 0.111 0.105 0.111 0.112 0.111 0.111 0.134 0.133 0.13 0.124
eAugbin 0.073 0.074 0.073 0.07 0.072 0.075 0.074 0.064 0.088 0.088 0.088 0.085
mAug 0.086 0.087 0.087 0.08 0.086 0.088 0.086 0.088 0.105 0.105 0.104 0.096
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Figure 1. Power of the three methods for fixed time as the mean log tumour size ratio (τ) varies and as
ψ varies at τ = .35.
Figure 2. Power of the binary method and mAug for best observed response for 4 time points as the
mean log tumour size ratio (τ) varies.
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